<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792360</url>
  </required_header>
  <id_info>
    <org_study_id>17-003774</org_study_id>
    <nct_id>NCT03792360</nct_id>
  </id_info>
  <brief_title>Adipose Derived SVF for Aero-digestive &amp; Enterocutaneous Fistulae</brief_title>
  <official_title>A Pilot Study: Evaluating the Safety and Feasibility of Using Autologous Adipose-Derived Stromal Vascular Fraction (SVF) for the Treatment of Aerodigestive &amp; Enterocutaneous Fistulae in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine safety and feasibility of using institutionally prepared autologous, uncultured SVF&#xD;
      on patients with aerodigestive and enterocutaneous fistulae secondary to malignancy, trauma&#xD;
      or surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this pilot study is to evaluate the feasibility, time, cost, safety,&#xD;
      limitations, and efficacy of the use of institutionally processed SVF for management and&#xD;
      closure of aero-digestive and enterocutaneous fistulae. This pilot study would help identify&#xD;
      design issues and the potential success of fistulae closure by the means of autologous SVF&#xD;
      administration before a full-scale trial is performed.&#xD;
&#xD;
      A secondary aim is the closure of aero-digestive and enterocutaneous fistulae along with&#xD;
      characteristics such as size, etiology, recurrence, localization, and the association of&#xD;
      these factors withoutcome after SVF administration. The SVF quantification, characterization&#xD;
      and differentiation in vitro will be described.&#xD;
&#xD;
      This process will help identify the type of fistulae that are susceptible to closure with&#xD;
      human cell therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2028</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2027</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Adverse Events from a single dose of autologous stromal vascular fraction (SVF) applied endoscopically into aerodigestive fistulae or enterocutaneous fistula [Safety and Tolerability].</measure>
    <time_frame>5 Years</time_frame>
    <description>Documentation of signs of adverse reactions from intravascular application of TISEEL, including: intravascular coagulation, thromboembolic events and acute hypersensitivity reactions. Documentation of signs of increased fistula size and/or aggravation of symptoms associated with fistulous tract, including: paroxysmal cough, dysphagia, wheezing, abdominal distention, chest pain, dyspnea, pneumonia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Adverse Events from liposuction procedure [Safety and Tolerability].</measure>
    <time_frame>5 Years</time_frame>
    <description>Signs of adverse reactions to the lipoaspiration procedure, including: allergic reaction to Hunstad solution, infection at the puncture wound site or risk of bleeding at the puncture wound site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of efficacy of Stromal Vascular Fraction's (SVF)'s ability to improve the success of surgical repair by fistulous tract reduction and/or closure.</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measurement and photography of the fistula in endoscopic/bronchoscopic evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of efficacy of Stromal Vascular Fraction's (SVF)'s ability to improve the success of surgical repair in reducing cardinal symptoms.</measure>
    <time_frame>5 Years</time_frame>
    <description>Documentation of reduction of cardinal symptoms by history and physical examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of efficacy of Stromal Vascular Fraction's (SVF)'s ability to prevent recurrence of aerodigestive fistulae or enterocutaneous fistulae.</measure>
    <time_frame>5 Years</time_frame>
    <description>Documentation of fistula recurrence by long term follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Tracheoesopharyngeal Fistula</condition>
  <condition>Bronchoesophageal Fistula</condition>
  <condition>Tracheoesophageal Fistula</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SVF (Stromal Vascular Fraction)</intervention_name>
    <description>The stromal vascular fraction (SVF), isolated when fresh lipoaspirates are enzymatically digested with a collagenase, contains a heterogeneous cellular and extracellular milieu. SVF is an aqueous fraction, consisting of endothelial cells and their precursors, macrophages, smooth muscle cells, lymphocytes, pericytes, pre-adipocytes and actual AMSCs.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 18 years old&#xD;
&#xD;
          -  Adults ≤ 90 years old&#xD;
&#xD;
          -  Fistula or sinus tract opening size between 2 mm and 15 mm in diameter (as measured by&#xD;
             comparing its size with the open mouth of a biopsy forceps)&#xD;
&#xD;
          -  Inpatient or outpatient setting&#xD;
&#xD;
          -  Recurrent or de novo fistulas or sinus tracts&#xD;
&#xD;
          -  A prior diagnosis of ADF OR ECF in which the standard therapy has failed or is not&#xD;
             applicable&#xD;
&#xD;
          -  Fistula or sinus tract location may include:&#xD;
&#xD;
          -  Tracheopharyngeal&#xD;
&#xD;
          -  Tracheoesophageal&#xD;
&#xD;
          -  Bronchoesophageal&#xD;
&#xD;
          -  Gastric, duodenal, jejunal, ileal, colonic or anastomotic -communicating to the skin&#xD;
             (cutaneous)&#xD;
&#xD;
          -  Esophogealgastric anastomosis&#xD;
&#xD;
          -  Mediastinal anastomotic leak&#xD;
&#xD;
          -  Fistula etiology may include:&#xD;
&#xD;
          -  Secondary to previous malignancy with complete remission&#xD;
&#xD;
          -  Secondary to radiotherapy as long as complete remission for 5 years has been achieved&#xD;
             and documented&#xD;
&#xD;
          -  Congenital with or without previous treatment&#xD;
&#xD;
          -  Secondary to surgical interventions or endoscopic therapies such as dilation and&#xD;
             esophageal manipulation&#xD;
&#xD;
          -  Post prolonged tracheal intubation&#xD;
&#xD;
          -  Secondary to inflammatory bowel disease&#xD;
&#xD;
          -  Secondary to foreign body ingestion&#xD;
&#xD;
          -  Secondary to thoracic trauma/crush injuries&#xD;
&#xD;
          -  Secondary to caustic ingestion&#xD;
&#xD;
          -  Secondary to pneumonectomy or mechanical ventilation&#xD;
&#xD;
          -  Esophagomalacia&#xD;
&#xD;
          -  The ability of subjects to give appropriate consent or have an appropriate&#xD;
             representative available to do so&#xD;
&#xD;
          -  The ability of subjects to return for follow up endoscopic assessment as established.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Exposure to any investigational drug or procedure within 3 months prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Patients with allergy to fibrin glue (TISSEEL) or anesthetics&#xD;
&#xD;
          -  Patients with active/ongoing malignancy such as esophageal, lung, tracheal, thyroid,&#xD;
             oropharyngeal or gastric cancer&#xD;
&#xD;
          -  Patients on active regimen of chemotherapy&#xD;
&#xD;
          -  Patients receiving radiation&#xD;
&#xD;
          -  Diabetics with poor glucose metabolic control exhibited by an HbA1c &gt; 9&#xD;
&#xD;
          -  If there is evidence, in endoscopy, of dysplastic-appearing mucosa such as Barrett's&#xD;
             dysplasia near the fistula or sinus tracts, this will be excluded. Patients that&#xD;
             require surgical intervention at the fistula or sinus tract area for any reason&#xD;
&#xD;
          -  BMI of &lt;16 (may difficult lipoaspiration procedure)&#xD;
&#xD;
          -  Women who are pregnant or nursing or women of childbearing potential who are unwilling&#xD;
             to maintain contraceptive therapy for the duration of the study&#xD;
&#xD;
          -  Clinical signs of respiratory tract or pleuro-pulmonary infections&#xD;
&#xD;
          -  Prolonged (&gt; 6 months) use of steroids&#xD;
&#xD;
          -  Patients with fistulae or sinus tracts &gt;15mm&#xD;
&#xD;
          -  Drug or alcohol dependence&#xD;
&#xD;
          -  Active infectious disease positive for HIV, HTLV, HBV, HCV, CMV (IgM &gt; IgG) and/or&#xD;
             syphilis&#xD;
&#xD;
          -  End of life&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhaumik Brahmbhatt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Strack</last_name>
    <phone>(904) 953 7971</phone>
    <email>Starck.Elizabeth@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Starck, CRC</last_name>
      <phone>904-953-7971</phone>
      <email>Starck.Elizabeth@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>December 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Bhaumik Brahmbhatt</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Fistula</mesh_term>
    <mesh_term>Tracheoesophageal Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03792360/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03792360/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

